Tracer library / [225Ac]Ac-DOTA-LM3
[225Ac]Ac-DOTA-LM3
Also written as [Ac-225]Ac-DOTA-LM3
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated somatostatin receptor subtype 2 (SSTR2) antagonist peptide (DOTA-LM3)
- Target / mechanism
- Somatostatin receptor subtype 2 (SSTR2) antagonist PMID 41599769
- Clinical application
- Targeted alpha therapy for metastatic neuroendocrine tumors, including cases refractory to prior 177Lu-based PRRT PMID 41599769
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | 86.7 ± 2.7% decay-corrected | >97% | DOTA-LM3 piCHEM, Raaba-Grambach, Austria | 41599769 2026 Pharmaceuticals (Basel) Radiolabeling of DOTA-LM3 with Actinium-225 was performed in a manual process in a shielded glove box - the average RCY was 86.7 ± 2.7% |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3.2026 · Clin Nucl Med · Clinical study
- TANDEM Peptide Receptor Radionuclide Therapy Using [ 225 Ac]Ac-/[ 177 Lu]Lu-DOTA-LM3 in a Patient With Parotid Gland Metastasis From Pancreatic Neuroendocrine Neoplasm.2025 · Clin Nucl Med · Case report
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- piCHEM
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-LM3, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41599769: 'DOTA-LM3'. Stage set/updated at stage 23 from PMID 41599769: 'In the reported patient, [225Ac]Ac-DOTA-LM3 therapy resulted in partial remission without clinically relevant hematologic, renal, or hepatic toxicity and was associated with marked clinical improvement.'. | Stage 30 (2026-09-18): Stage was 'first-in-human'; normalised to 'Clinical research', original wording kept here.